This study investigates the association of CRP single nucleotide polymorphisms (SNPs) with plasma CRP levels and radiographic severity in African Americans with early and established rheumatoid arthritis (RA). Using a cross-sectional case-only design, CRP SNPs were genotyped in two independent sets of African Americans with RA: Consortium for the Longitudinal Evaluation of African Americans with RA (CLEAR 1) and CLEAR 2. Radiographic data and CRP measurements were available in 294 individuals from CLEAR 1 [median (IQR 25-75) disease duration of 1 (0.6-1.6) year] and in 407 persons from CLEAR 2 [median (IQR 25-75) disease duration of 8.9 (3.5 -17.7) years]. In CLEAR 1, in adjusted models, the minor allele of rs2808630 was associated with total radiographic score [incident rate ratio (IRR) 0.37 (95% CI 0.19-0.74), p value =0.0051]. In CLEAR 2, the minor allele of rs3093062 was associated with increased plasma CRP levels (p value =0.002). For each rs3093062 minor allele, the plasma CRP increased by 1.51 (95% CI 1.15-1.95) mg/dL when all the other covariates remained constant. These findings have important implications for assessment of the risk of joint damage in African Americans with RA.
INTRODUCTION
Rheumatoid arthritis (RA), a common form of inflammatory arthritis affecting synovial joints, has a variable clinical expression ranging from mild disease to severe joint destruction 1 . Although the biological processes underlying the pathophysiology of RA are not completely understood, systemic inflammation, as reflected by serum CRP levels, is thought to represent a key component. CRP is found in the synovial fluid of RA patients 2 and can bind to lymphocytes, monocytes and other inflammatory cells [3] [4] [5] . Serum CRP level is commonly used to assess disease activity in RA patients 6 and is part of the Disease Activity Score in 28 joints (DAS28-CRP) 7 . Serum CRP levels are also included in the American College of Rheumatology (ACR) treatment response criteria 8 . The importance of serum CRP in RA is also highlighted by the finding that levels of this acute phase reactant influences physicians' decisions in changing treatment in RA 9 .
Single nucleotide polymorphisms (SNPs) in CRP have been shown to be associated with serum CRP levels [10] [11] [12] [13] and their biologic role has been evaluated in different disease states including RA, cardiovascular disease, Alzheimer's disease, colorectal cancer, and chronic kidney disease 10 , [14] [15] [16] [17] . For instance, among African-Americans without known cardiovascular disease, the minor allele of the CRP SNP rs3093058 is associated with higher serum CRP levels, while the minor allele of rs1205 is associated with lower CRP serum levels 12 .
There is great variability in the minor allele frequency (MAF) of CRP SNPs among different ethnic groups 10 , 18 . CRP SNP rs3093058 is part of a haplotype associated with incident stroke in African-Americans 12 , but this SNP is monomorphic (MAF=0) in EuropeanAmericans and thus does not contribute to the risk of stroke in that ethnic group 12 . Furthermore, the MAF of another haplotype-tagging SNP in CRP (rs3093066) is 0.23 in African-Americans, but this locus is monomorphic in persons of European ancestry 18 . Given the relevance of CRP to RA pathogenesis and clinical decision making, such differences in genotype distributions could have important implications for pathogenesis in patients with RA.
CRP is indisputably a component of the inflammatory process in RA, and plasma CRP levels are associated with radiographic damage among RA patients 19 . However, the relationship between radiographic damage in RA and genetic variants within CRP has not explicitly been investigated, particularly in understudied ethnic minority populations. In the current study, we measured plasma CRP levels and genotyped 11 polymorphic SNPs in CRP in a sample of well-characterized African Americans with RA with early disease (CLEAR 1) and with predominantly long-standing disease (CLEAR 2). Thus, these analyses provide insight into the role of CRP at different phases of the disease. Specifically, we tested whether CRP polymorphisms were associated with radiographic severity and with plasma CRP levels in early and longstanding disease to evaluate whether systemic inflammation and RA-induced joint damage have common genetic determinants.
RESULTS
The baseline characteristics of the study samples are presented in Table 1 . More detailed information about the clinical characteristics of the CLEAR participants has been previously published 20 . Table 1 shows that compared with African Americans with RA from CLEAR 1 subset, the participants enrolled in CLEAR 2 had more radiographic damage, were older, had longer disease duration, a lower median tender joint count, were more likely to be autoantibody positive (RF and ACPA). In addition, there were differences in use of DMARDs and biologic agents. 
Associations of CRP polymorphisms with total radiographic scores
The median (IQR 25-75) mTSS at enrollment in CLEAR 1 was 0 (0-2), while in CLEAR 2, the median (IQR 25-75) mTSS was 6 (0-31), as previously reported 20 Table 3) . None of the CRP SNPs was associated with radiographic severity in CLEAR 2 after adjusting for relevant covariates (Table 4) .
Associations of CRP polymorphisms with plasma CRP levels
The results of the univariate and multivariate analyses for the associations of CRP polymorphisms with baseline plasma CRP are shown in Tables 5 and 6 
DISCUSSION
This is the first study to evaluate the association of genetic variation in CRP locus with joint damage in RA and is focused on an important minority racial/ethnic group. We found that rs2808630 in the CRP 3' flanking region was associated with radiographic damage in early RA (CLEAR 1) and identified statistically significant associations between a CRP promoter region SNP, rs3093062, and higher levels of plasma CRP in African Americans with established RA. Our results are concordant with a recent report from Plant et al. 22 , which found that CRP rs3093062 was associated with increased plasma CRP in RA patients from the UK. However, in contrast to Rhodes et al. 13 , we did not find an association between CRP SNPs rs1205 and plasma CRP levels in early RA, possibly due to differences in ethnicity (UK, New Zealand and Australians). Most importantly, we found that the CRP locus influences both radiographic damage and plasma CRP levels at different stages of the disease. A possible explanation for the finding of different CRP SNPs associated with phenotypes in early and established disease is that there are significant differences in the clinical and demographic characteristics between the two groups analyzed, early vs established. Alternatively, it is possible that the pathobiology of early RA is different than that of established RA (i.e. the activity of different transcription factors is affected by CRP
SNPs in early versus established RA). In an attempt to test this theory, we analyzed the association of rs2808630 and total radiographic scores in 60 CLEAR 2 participants with disease duration of less than 2 years. We found that the CRP rs2908630 was not associated with less radiographic damage (IRR =0.61, p=NS), but the direction of the effect was similar to the results obtained in CLEAR1. This result suggests that future studies of CRP genetic variation and radiographic severity are warranted in early RA.
A major strength of this study is that it analyzes the largest group of African Americans with RA available to date. Several clinical (age, sex, disease duration, medication use, disease activity), laboratory (autoantibody positivity, CRP level, ESR), genetic (HLA DRB1 shared epitope) and environmental (smoking) factors previously reported to contribute to structural joint damage in RA 23 , 24 . This paper is the first to provide evidence of a CRP genetic contribution to structural joint damage in African Americans with RA, independent of age, gender, disease duration, DMARD use, and autoantibody status (RF and ACPA status). The association of CRP SNP rs2808630 with lower radiographic damage has biological plausibility, because of previous literature supporting an association between this variant and lower CRP levels in a much larger sample of African Americans (~2,100) from the Third National Health and Nutrition Examination Survey (NHANES III) 10 .
Previous studies have shown that the radiographic damage in RA is heritable, with the h 2 estimate ranging from 45 to 58% 25 . Our study adds to the growing body of evidence in support of genetic associations with radiographic severity in multiple populations: IL1 cluster 26 37 . There is mixed support in the literature for a correlation between HLA-DRB1 SE alleles and radiographic damage 28 , 37-40 27 . We did not specifically include any of these non-HLA loci in our models, but we did include HLA-DRB1 SE status and did not find an association of SE status and radiographic severity. This is consistent with findings of Khanna et al. in a study of Caucasians with early RA 27 . In our study, the absence of association between SE alleles and radiographic severity may be due to a lower frequency of HLA-DRB1 SE alleles in African Americans compared to European ancestry RA 41 .
The present study represents a candidate SNP approach aimed at defining the contribution of 7 CRP polymorphisms to joint damage in RA. Future fine mapping of CRP may identify more genetic variants linked to radiographic severity and plasma CRP levels in African Americans with RA. Because our study included only African Americans, the association of CRP variants with radiographic severity is not generalizable to the entire population of patients with RA and further studies in other ethnicities are needed to address this issue.
In summary, among African Americans with early RA after taking in consideration clinical relevant factors, CRP rs2808630 is associated with lower radiographic damage, while CRP rs3093059 is associated with increased plasma CRP levels in African Americans with RA independent of other factors. These findings have important implications for assessment of disease activity and risk of erosive disease in African Americans with early RA.
MATERIALS AND METHODS

Study population
The CLEAR 1 Registry enrolled African Americans with RA between 2000 and 2005 and included only patients with less than 2 years disease duration. CLEAR 2 enrolled African Americans with RA between 2006 and 20#11 and included RA of any disease duration 20 . Patients enrolled in CLEAR 1 were not enrolled in CLEAR 2, so there was no overlap in the patient populations. All participants met revised 1987 American Rheumatism Association (now the American College of Rheumatology) criteria 42 , and were self-declared AfricanAmericans of 19 years of age and older. After signing informed consent, the participants were recruited in Alabama (University of Alabama at Birmingham -Coordinating Center), Georgia (Emory University), North Carolina (University of North Carolina at Chapel Hill), Missouri (Washington University), and South Carolina (The Medical University of South Carolina). Peripheral blood was collected for measurement of rheumatoid factor (RF), anticyclic citrullinated peptide antibodies (ACPA), plasma CRP and for isolation of genomic DNA. Questionnaires were administered to document current and previous drug treatments with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. We included in this analysis sets of page#11hand/wrists (postero-anterior views) and feet (anteroposterior views) radiographs obtained at enrollment and scored using the modified Sharp/van der Heijde scoring system and assigned a modified total Sharp score (mTSS) 20 , 43 . Participants provided written informed consent and human subject protocols were approved by the Institutional Review Boards of the participating institutions.
The following socio-demographic variables were included as covariates in the analyses: age at enrollment, sex, disease duration, body mass index (BMI), and smoking status (ever vs. never). The clinical variables included were: tender and swollen joint counts (assessed in 28 joints -shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees), usage of methotrexate and other DMARDs, biologic agents, and corticosteroids.
CRP levels (mg/L) were measured on plasma samples from the enrollment visits at the Clinical and Epidemiological Research Laboratory at Children's Hospital in Boston using a high-sensitivity immunoturbidimetric assay on a Hitachi 917 autoanalyzer (Roche Diagnostics, Indianapolis, IN), with the use of reagents and calibrators from Denka Seiken (Tokyo, Japan). High levels of CRP were defined as > 3 mg/L 44 . RF and ACPA were assayed as previously reported 45 . We measured plasma rather than serum CRP levels because of the availability of plasma specimens for our study population and because the measurement of CRP in plasma and serum are comparable 46 .
Genotyping methods
Eleven CRP SNPs (rs3093058, rs3093059, rs2794521, rs3093061, rs3093062, rs3091244, rs1417938, rs1800947, rs3093066, rs1205, rs2808630) were selected for genotyping based on several criteria at the time of study inception: disease associations reported in the literature; minor allele frequency > 5% in published databases; or potential biological function 10 , 11 , 18 , 47 , 48 (see Table 2 ). For 347 CLEAR 1 participants and 143 CLEAR 2 participants, 9 of the CRP SNPs were genotyped using Applied Biosystems (ABI) TaqMan ® Genotyping Assays, (Foster City, CA) on an ABI 7900HT Sequence Detection System with a call rate of greater than 99%. The tri-allelic SNP rs3091244 SNP and the bi-allelic SNP rs3093061 were genotyped by Pyrosequencing 49 using Biotage (Charlotte, NC) reagents and protocol; the call rate for both was 99%. For 440 CLEAR 2 participants, genotype data of rs3093059, rs2794521, rs3093062, rs3093066, rs1205, rs2808630 were available as part a of a previous genotyping effort through the Immunochip (iChip) custom array by Illumina (San Diego, CA); these markers had a call rate greater than 98.5%. One CRP polymorphism (rs1800947) had a MAF of 0.005 and thus was not included in the analysis. HLA DRB1 genotyping was performed using the Atria Genetics (South San Francisco, CA) AlleleSEQR DRB1 reagents and protocol as previously described 41 .
Statistical methods
Means (SD) were calculated for normally distributed continuous variables and proportions were calculated for categorical variables. Student t tests and chi square tests were used to evaluate differences between continuous and categorical variables, respectively. Linkage disequilibrium (LD) between biallelic SNP pairs was analyzed using Haploview 50 (Supplemental Figure 1) . CRP polymorphisms rs3093061, rs3093058, and rs3093062 were in tight LD (pairwise r 2 > 0.8), as were rs2808630 and rs2794521; only one CRP SNP from each of these two sets (rs3093062 and rs2808630) was included in the data analysis. As noted above, one CRP polymorphism (rs1800947) had a MAF of < 1% and was excluded from the data analysis. Genotype data for CRP SNPs rs3091244 and rs1417938 was available for analysis in only 140 (~34%) CLEAR 2 participants. There were no significant differences in the MAF of the CRP SNPs between CLEAR 1 and CLEAR 2 (data not shown). Deviation from HWE for each of the CRP polymorphisms was assessed using Haploview. All the CRP SNPs analyzed were in HWE.
We performed separate data analysis in the two study groups: CLEAR 1 and CLEAR 2 for several reasons, including different enrollment periods (2000 -2005 for CLEAR 1; 2006 -2011 for CLEAR 2), different available medications, different disease duration, and differences in degree of radiographic damage. Complete data on genotypes, radiographic scores, and CRP measurements were available for 294 (83%) of the 355 CLEAR 1 participants and 407 (57%) of the 712 CLEAR 2 participants. There were no statistically significant differences in clinical and biochemical characteristics between the persons for whom radiographs were available and the entire study population (data not shown).
The modified total radiographic score (mTSS) for these two groups of patients was overdispersed, with the majority having no damage (mTSS=0) in 200 (68%) of CLEAR 1, and 248 (61%) of CLEAR 2 participants. Thus, negative binomial models were fitted to evaluate the association of CRP genotypes (explanatory variable) with the mTSS (dependent variable) in an additive genetic model framework. Given the positively skewed distribution of the plasma CRP levels, these values were log-transformed for the purposes of the analysis. Linear regression was used to investigate the relationship between CRP genotypes and log transformed plasma CRP levels, assuming an additive genetic model of inheritance. Demographic and clinical variables with p value < 0.25 in the univariate analyses were included in the multivariate analyses 51 . In addition, since gender, CRP levels and traditional and biologic DMARD use have been shown to affect the progression of radiographic joint damage, these covariates were included in multivariable models with mTSS as the outcome variable. Table 1 Characteristics of African American participants with RA from CLEAR registry. Table 2 CRP variants studied in African Americans with rheumatoid arthritis. Table 3 CRP genotypes associations with total radiographic score in African Americans from CLEAR 1. Table 4 CRP genotypes associations with total radiographic score in African Americans from CLEAR 2. Abbreviations: ACPA, anti-cyclic citrullinated peptide antibodies; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; DMARDs, disease modifying anti-rheumatic drugs; IRR, incident rate ratio; RA, rheumatoid arthritis; RF, rheumatoid factor; SE, shared epitope. Table 5 CRP genotypes associations with log transformed plasma CRP in African American from CLEAR 1. Table 6 CRP genotypes $ associations with log transformed plasma CRP in African Americans from CLEAR 2. Abbreviations: ACPA, anti-cyclic citrullinated peptide antibodies; BMI, body mass index; CI, confidence interval; CRP, C-reactive protein; DMARDs, disease modifying anti-rheumatic drugs; RF, rheumatoid factor; SE, shared epitope $ Additive model minor allele (0 vs 1 vs 2) after adjusting for age, gender, BMI, RF and ACPA status, corticosteroid use, number of swollen joints, number of tender joints. Statistically significant differences (as defined by Bonferroni corrected p value <0.0071) are in bold characters.
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Additive model minor allele (0 vs 1 vs 2) after adjusting for age, gender, BMI, RF and ACPA status, corticosteroid use, number of swollen joints, number of tender joints, European admixture. Statistically significant differences (as defined by Bonferroni corrected p value <0.0071) are in bold characters
